OXALIPLATINE TEVA 5 mg/ml, concentrate for solution for infusion bottle, CIP 3400957187132
Active ingredients: Oxaliplatin
Commercialized according to BDPMDispensing in France: Prescription only
Concentrate for solution for infusionbottle, CIP 3400957187132intraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- OXALIPLATINE TEVA 5 mg/mL, solution à diluer pour perfusion
- Pharmaceutical form
- solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 50 mg
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Oct 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69634537CIP75718713CIP133400957187132Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| OXALIPLATINEsolution | 5 mg · 1 ml de solution à diluer | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.